GRIFOLS S A/S (GRFS) Receives $20.00 Consensus Target Price from Analysts

GRIFOLS S A/S (NASDAQ:GRFS) has been given an average rating of “Hold” by the ten research firms that are covering the company, MarketBeat reports. Four equities research analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $20.00.

Several equities analysts have recently commented on the stock. Zacks Investment Research upgraded shares of GRIFOLS S A/S from a “sell” rating to a “hold” rating in a report on Friday, June 22nd. BidaskClub upgraded shares of GRIFOLS S A/S from a “strong sell” rating to a “sell” rating in a report on Saturday, July 28th. Morgan Stanley decreased their price objective on shares of GRIFOLS S A/S from $22.00 to $20.00 and set an “underweight” rating on the stock in a report on Monday, October 1st. Berenberg Bank upgraded shares of GRIFOLS S A/S from a “hold” rating to a “buy” rating in a report on Thursday, October 11th. Finally, UBS Group lowered shares of GRIFOLS S A/S from a “neutral” rating to a “sell” rating in a report on Wednesday, October 3rd.

Shares of GRFS stock traded down $0.04 during trading hours on Friday, hitting $19.73. The company had a trading volume of 954,600 shares, compared to its average volume of 877,046. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.12 and a current ratio of 2.90. GRIFOLS S A/S has a fifty-two week low of $18.69 and a fifty-two week high of $25.18. The firm has a market cap of $14.59 billion, a P/E ratio of 17.97, a P/E/G ratio of 1.49 and a beta of 1.21.

GRIFOLS S A/S (NASDAQ:GRFS) last issued its quarterly earnings data on Friday, July 27th. The biotechnology company reported $0.34 EPS for the quarter, hitting the consensus estimate of $0.34. GRIFOLS S A/S had a net margin of 16.55% and a return on equity of 18.32%. The firm had revenue of $1.31 billion for the quarter, compared to analyst estimates of $1.35 billion. As a group, research analysts predict that GRIFOLS S A/S will post 1.21 EPS for the current fiscal year.

Several hedge funds have recently modified their holdings of the company. Vaughan Nelson Investment Management L.P. lifted its holdings in GRIFOLS S A/S by 5.1% during the 2nd quarter. Vaughan Nelson Investment Management L.P. now owns 3,021,901 shares of the biotechnology company’s stock worth $64,971,000 after buying an additional 147,715 shares in the last quarter. SG Americas Securities LLC lifted its holdings in GRIFOLS S A/S by 38,886.6% during the 2nd quarter. SG Americas Securities LLC now owns 3,001,189 shares of the biotechnology company’s stock worth $64,526,000 after buying an additional 2,993,491 shares in the last quarter. Engadine Partners LLP lifted its holdings in GRIFOLS S A/S by 18.0% during the 2nd quarter. Engadine Partners LLP now owns 2,906,319 shares of the biotechnology company’s stock worth $62,486,000 after buying an additional 443,386 shares in the last quarter. First Trust Advisors LP lifted its holdings in GRIFOLS S A/S by 26.8% during the 2nd quarter. First Trust Advisors LP now owns 2,495,308 shares of the biotechnology company’s stock worth $53,649,000 after buying an additional 527,595 shares in the last quarter. Finally, Millennium Management LLC lifted its holdings in GRIFOLS S A/S by 17.9% during the 1st quarter. Millennium Management LLC now owns 1,488,055 shares of the biotechnology company’s stock worth $31,547,000 after buying an additional 226,173 shares in the last quarter. Hedge funds and other institutional investors own 21.05% of the company’s stock.

GRIFOLS S A/S Company Profile

Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others.

Read More: What is a Stop Order?

Analyst Recommendations for GRIFOLS S A/S (NASDAQ:GRFS)

Receive News & Ratings for GRIFOLS S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRIFOLS S A/S and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply